source
- Shionogi makes $2B rare disease play with IntraBio buyWith its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…BioSpace · 1mo ago↗ source
- FDA extends review of Novo’s hemophilia A drug, citing manufacturing issuesDespite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.BioSpace · 1mo ago↗ source
- Vaxcyte’s VAX-31 shows superior results in Phase 3, beating Pfizer and Merck’s pneumococcal vaccines and sparking $8 bn market hopesVaxcyte reported that its investigational pneumococcal conjugate vaccine, VAX-31, met the co-primary endpoints in a Phase 3 trial, demonstrating non-inferiority to the existing shots from Pfizer an…